Production & Sales

Symbiosis gets FDA approval for manufacturing fill/finish process

Sterile manufacturing CDMO Symbiosis Pharmaceutical Services has secured approval from the US Food and Drug Administration (FDA) for its viral vector manufacturing fill/finish process at its biologics manufacturing facility in Scotland, UK.

Lonza adds two new Ibex solutions offerings to Swiss biopark

Swiss multinational, chemicals and biotechnology firm Lonza has added two new Ibex solutions offerings to its 100,000m² biopark in Visp, Switzerland.

Grifols secures FTC’s conditional approval for Biotest US acquisition

The US Federal Trade Commission (FTC) has approved a final order which requires Grifols to sell certain assets as a condition for its acquisition of Biotest US in accordance with the federal antitrust law.

Norgine to commercialize Shield’s iron deficiency therapy in Europe, Australia and New Zealand

Shield Therapeutics and Norgine have entered into an exclusive licence agreement in Europe, Australia and New Zealand, under which Norgine will commercialise Feraccru, Shield’s approved product for the treatment of iron deficiency in adults.

BeiGene selects GE’s KUBio facility to boost cancer drugs manufacturing capacity

GE said that global biotech company BeiGene has selected KUBio, GE Healthcare Life Sciences’ off-the-shelf biomanufacturing facility, to increase its manufacturing capacity for cancer drugs.

Regeneron to invest $800m in New York expansion

Biotechnology company Regeneron will invest about $800m over seven years to expand its laboratory space, manufacturing capacity and warehouse facilities at the company's Rensselaer County campus and create 1,500 new full-time jobs in the greater Capital Region.

Carlyle buys minority stake in US CDMO Ambio from MVM Partners

The Carlyle Group, a global alternative asset manager, has acquired a minority stake in Ambio, a US-based global peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO), from specialist healthcare fund MVM Partners.

Drugmaker GSK to cut 650 jobs in US

British pharma giant GlaxoSmithKline (GSK) is set to lay off 650 employees in its US operations in line with a global restructuring strategy announced in July this year.

US hospital groups establish not-for-profit generic drug company

Civica Rx, the initiative earlier known as Project Rx, is the name of a new not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving medications.